Circulating CD36+ microparticles are not altered by docosahexaenoic or eicosapentaenoic acid supplementation

Nutrition, Metabolism, and Cardiovascular Diseases : NMCD
Melinda PhangLisa F Lincz

Abstract

Circulating microparticles (MP) are the source of a plasma derived form of the scavenger receptor CD36, termed soluble (s)CD36, the levels of which correlate with markers of atherosclerosis and risk of cardiovascular disease. Long chain n-3 polyunsaturated fatty acids have cardioprotective effects that we have previously reported to be gender specific. The aim of this study was to determine if dietary docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA) supplementation affect circulating CD36 + MP levels, and if this occurs differentially in healthy men and women. Participants (43M, 51F) aged 39.6 ± 1.7 years received 4 weeks of daily supplementation with DHA rich (200 mg EPA; 1000 mg DHA), EPA rich (1000 mg EPA; 200 mg DHA), or placebo (sunola) oil in a double-blinded, randomised, placebo controlled trial. Plasma CD36 + MP were enumerated by flow cytometry and differences between genders and treatments were evaluated by Student's or paired t-test and one way ANOVA. Males and females had similar levels of CD36 + MP at baseline (mean = 1018 ± 325 vs 980 ± 318; p = 0.577) and these were not significantly changed after DHA (M, p = 0.571; F, p = 0.444) or EPA (M, p = 0.361; F, p = 0.901) supplementation. Likewise, the over...Continue Reading

References

Aug 10, 1999·Critical Reviews in Oncology/hematology·L L Horstman, Y S Ahn
Aug 31, 2000·Biochemical and Biophysical Research Communications·P GruarinM Alessio
Sep 6, 2008·The American Journal of Pathology·Abdelali AgouniRamaroson Andriantsitohaina
Dec 18, 2008·European Journal of Clinical Investigation·D BulutA Mügge
Mar 12, 2009·Thrombosis and Haemostasis·Laurent BurnierAnne Angelillo-Scherrer
Apr 25, 2009·Cleveland Clinic Journal of Medicine·Roy L Silverstein
Feb 1, 2011·Journal of Thrombosis and Haemostasis : JTH·M J AlkhatatbehR F Thorne
Apr 13, 2011·Journal of Thrombosis and Haemostasis : JTH·W L ChandlerJ F Tait
Jun 30, 2011·Thrombosis and Haemostasis·Gala TsimermanAnat Aharon
Dec 6, 2011·The Journal of Nutritional Biochemistry·Melinda PhangManohar Lal Garg
Aug 21, 2012·Journal of Lipid Research·Donald B JumpSasmita Tripathy
Sep 13, 2012·JAMA : the Journal of the American Medical Association·Evangelos C RizosMoses S Elisaf
Feb 6, 2013·Nutrition & Diabetes·M J AlkhatatbehL F Lincz
Feb 23, 2013·Journal of Cardiovascular Pharmacology·Daniel BulutAndreas Mügge
Jun 25, 2013·Journal of Physiology and Biochemistry·Silvia Lorente-CebriánMaría J Moreno-Aliaga
Feb 24, 2015·Journal of Intensive Care·Shosaku Nomura, Michiomi Shimizu

❮ Previous
Next ❯

Citations

Mar 16, 2021·Frontiers in Cardiovascular Medicine·Che Mohd Nasril Che Mohd NassirMuzaimi Mustapha

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.